- Details
- Description
Packaging Size:
10 capsules
Strength:
125 mg
Composition:
Dordaviprone 125 mg
Treatment:
Diffuse midline glioma (DMG) with H3K27M mutation
Form:
Hard capsules
Brand:
LuciDorda
Quantity Unit:
Capsules
Manufacturer:
Lucius Pharmaceuticals (Lao) Co., Ltd.
LuciDorda (Dordaviprone) is a targeted medicine containing dordaviprone, a small-molecule inhibitor of the dopamine D2 receptor and an activator of the integrated stress response pathway. It is designed to affect cellular pathways involved in tumor growth and survival.
Dordaviprone is used for the treatment of adult patients with diffuse midline glioma (DMG) with an H3 K27M mutation, a rare and aggressive type of brain tumor. Treatment is intended for patients whose disease has progressed following prior therapy.
LuciDorda is an oral medicine and should be used under the supervision of a qualified healthcare professional following appropriate diagnostic confirmation of the tumor's molecular characteristics.
